What AI says about Lindus Health

Lindus Therapeutics licenses phase 1-ready or early data clinical assets and develops them through an integrated trial operating model to take programs further, faster. The company uses an in-house trial delivery platform and AI-assisted processes to automate workflows, directly recruit patients, and provide real-time data, accelerating enrollment and readouts. With global trial execution across the US, UK, and Europe and a focus on non-ultra-rare chronic diseases, Lindus builds an asset portfolio internally and pursues licensing or partnerships, targeting initial deals by 2026 and first trials in 2027.